Combination Intraventricular Chemotherapy Pilot Study: Methotrexate and Etoposide Infusions into the Fourth Ventricle or Resection Cavity in Children with Recurrent Posterior Fossa Brain Tumors
Lead Physician: David Sandberg, M.D.
The
Children’s Neuroscience Center has a new brain tumor trial that is open to
qualified participants. The research study is being conducted by David
Sandberg, M.D., Professor and Director of Pediatric Neurosurgery at McGovern
Medical School at UTHealth and Children’s Memorial Hermann Hospital. The study
is called “Combination Intraventricular Chemotherapy Pilot Study: Methotrexate
and Etoposide Infusions into the Fourth Ventricle or Resection Cavity in
Children with Recurrent Posterior Fossa Brain Tumors.”
It is open to patients
who are age 1 to 21 years old with recurrent medulloblastoma (PNET), recurrent
ependymoma, and recurrent atypical teratoid/rhabdoid tumors involving the brain
and/or spine.
The
study employs a novel means of treating malignant tumors that originate from
the fourth ventricle: infusion of two chemotherapy agents directly into the
fourth ventricle rather than systemic intravenous delivery. There will be no
simultaneous systemic chemotherapy. This study is listed at ClinicalTrials.gov, NCT #02905110,under
“Brain Tumor Recurrent.” If you would like additional information about this
study, please contact Bangning Yu, M.D., Ph.D., by email at Bangning.Yu@uth.tmc.edu or call (713)
500-7363.